Radiatric Inc.
Radiatric Inc. is dedicated to developing and commercializing innovative technologies to improve outcomes for patients with bacteremia, moderate to severe sepsis, and septic shock. Their flagship product, the RAD-01 system, is a non-antibiotic investigational device designed to treat bloodborne infections by lowering pathogenic CFUs in extracorporeal blood. The company focuses on non-pharmacological methods to deactivate pathogens, aiming to reduce the mortality and long-term effects associated with sepsis.
What We Do
A patent-pending non-antibiotic investigational device for treating bacteremia and lowering pathogenic CFUs in extracorporeal blood to improve outcomes in bloodborne infections and severe sepsis. It works with existing dialysis, CRRT, and hemoperfusion machines to treat blood using visible light, deactivating pathogens without harming human cells.
Infectious Diseases
Biologics
Key People
President
VP Research and Development